share_log

山东新华制药股份(00719.HK):全资子公司头孢克洛胶囊通过仿制药一致性评价

Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Wholly-owned subsidiary cefaclor capsules passed generic drug consistency evaluation

Gelonghui Finance ·  Apr 10 04:38

Gelonghui, April 10 | Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that recently, Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinda Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for cefaclor capsules (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. The product passed the consistent evaluation of the quality and efficacy of generic drugs.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment